Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 16, 2020updated 04 Jan 2022 12:23pm

Men, the elderly and people with pre-existing conditions most likely to die due to coronavirus, official data confirms

By Paul Dennis

COVID-19 was the third most common cause of death in England and Wales last month, new Office Of National Statistics (ONS) data reveals.

Almost one in ten deaths in March involved Covid-19. The number is an average across the entire month – including the early days before the outbreak took hold – and is expected to be higher in April as the virus spread rapidly.

The figures come from an in-depth ONS study of all deaths in March registered up to April 6 where Covid-19 was involved.

It found more than nine in ten people who died due to a Covid-19 infection had a pre-existing health condition. The average number of pre-existing conditions was 2.7 – meaning many of the people who died had at least three.

Some 14 per cent of those who died had ischaemic heart disease – making it the most common pre-existing complaint, followed by pneumonia, dementia and chronic obstructive pulmonary disease.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Men had a significantly higher rate of death due to Covid-19 – almost double that of women. The data also confirmed that the elderly were disproportionately likely to die, with death rates increasing rapidly from the ages of 55-59 for men and 65-69 for women. Children seem to be virtually unaffected by the disease, with no deaths of people under 15 recorded in March.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU